• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Financial Services·OWL
Share

Blue Owl Capital Inc. Stocks

$ 9.47Last Updated 10.06.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

$ 14.91B

$ 9.47
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

04.06.2026 23:04

Blackstone has for the first time restricted withdrawals from its private credit fund

08.05.2026 00:29

The value of BlackRock and BlackStone private credit funds fell due to borrower debt

01.05.2026 08:00

Blue Owl reveals profit on SpaceX investment, shares rise. Is the fund saved?

30.04.2026 00:30

Private credit funds have become a trap for wealthy investors - Ken Griffin

21.04.2026 16:04

Morning in New York: focus on the change of the Fed's head

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Blue Owl Capital Inc., an asset management firm based in New York City, leverages a robust and permanent capital base to deliver a comprehensive suite of financial solutions. It serves a diverse clientele, including mid-sized businesses, leading alternative asset managers, and corporate real estate owners and tenants. The company's offerings encompass direct lending products, providing private credit options such as diversified, technology-focused, first lien, and opportunistic financing for middle-market companies. Additionally, it offers GP capital solutions, extending financial backing to major private capital managers through services like minority equity investments, GP debt financing, and stakes in professional sports organizations. Blue Owl also provides real estate-focused products, primarily involving the structuring of sale-leaseback transactions, often featuring triple net leases. These diverse solutions are made available through permanent capital vehicles and long-term private investment funds.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of OWL is 13 and suggests 41% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.06.2026 18:17

Trump has vowed to launch more strikes against Iran. Iran threatened to attack Musk's companies

11.06.2026 17:45

Italy's SJI promoted "Superjets" abroad. How does it survive under sanctions?

11.06.2026 17:26

ECB raises rate for first time since 2023

11.06.2026 17:00

IPO hopes and dreams: why iconic shortstop Jim Chanos doesn't believe SpaceX's valuation

11.06.2026 16:35

FDA decisions and clinical data: the main drivers in small-cap biotech through the end of June

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026